Clinical trials: filgrastim
Leukemia, Myelodysplastic Syndromes
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
RATIONALE: Giving chemotherapy, natural killer cells, aldesleukin, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal cells and cancer cells.
- Trial name
- NCT00354172
- Testing
- aldesleukin, filgrastim, natural killer cell (NK) therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gynecologic Cancer, Myelosuppression Adult
G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients.
- Conditions
- Gynecologic Cancer, Myelosuppression Adult, Febrile Neutropenia, Chemotherapy-induced Neutropenia
- Trial name
- NCT03793205
- Testing
- Long-acting G-CSF, Short-acting G-CSF
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ivosidenib when given together with combination chemotherapy for the treatment of 1DH1 mutant acute myeloid leukemia that is newly diagnosed (previously untreated), has…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04250051
- Testing
- Cytarabine, Filgrastim, Fludarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005977
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- 119 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- Children's Oncology Group
Retinoblastoma
Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma
The investigators are testing subtenon carboplatin in combination with vincristine and topotecan given by vein in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back (recurrent)…
- Trial name
- RELRB1 (NCT00980551)
- Testing
- subtenon Carboplatin, Topotecan Hydrochloride, Vincristine
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Relapsed/Refractory AML
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
This is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of CLAG+VEN and CLAG regimens in relapsed/refractory(r/r) AML.
- Trial name
- NCT06763666
- Testing
- Cladribine, Cytarabine, G-CSF
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Crohn's Disease
Autologous Stem Cell Transplantation for Crohn's Disease
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients…
- Trial name
- NCT00692939
- Testing
- autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Paul Szabolcs
Chemotherapy-induced Neutropenia
Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/granulocyte colony-stimulating factor fusion protein by injection for preventing neutrophilic granulocytopenia among chemotherapy patients.
- Trial name
- NCT02465801
- Testing
- HSA-GCSF 1.2 mg, HSA-GCSF 1.5 mg, GCSF
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Non-Hodgkin's Lymphoma
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.
- Trial name
- NCT01164475
- Testing
- Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 61 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma
Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00003929
- Testing
- filgrastim, lomustine, procarbazine hydrochloride
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery or radiation therapy may shrink the tumor so that it can be removed…
- Trial name
- NCT00025077
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Lymphoma
Dose-Dense Therapy in Aggressive Lymphoma
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.
- Trial name
- NCT00517894
- Testing
- CEOP/IMVP-Dexa chemotherapy
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation
The MAC-HAPLO-MUD trial is a randomized prospective phase III trial comparing HLA 10/10 matched unrelated donor and haploidentical allogeneic hematopoietic stem cell transplantation after myeloablative conditioning regimen in…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myeloproliferative Syndromes, Myelodysplastic Syndromes
- Trial name
- MacHaploMud (NCT03655145)
- Testing
- Haplo donor stem cell transplantation, HLA 10/10 MUD stem cell transplantation
- Volunteers
- 344 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pegfilgrastim-induced Back and Leg Pain
Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain
The purpose of this study is to determine the incidence of pegfilgrastim-induced back and leg pain and to determine whether the antihistamine loratadine can prevent pegfilgrastim-induced back and leg pain.
- Trial name
- NCT01311336
- Testing
- Loratadine
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Vermont
Biliary Atresia
GCSF Adjunct Therapy for Biliary Atresia
The Investigators propose to test the hypothesis that GCSF therapy enhances the clinical outcome of Kasai operated Biliary Atresia (BA) patients.
- Trial name
- BA_GCSF (NCT03395028)
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 6 people
- Sponsor
- Holterman, Ai-Xuan, M.D.
Small Cell Lung Cancer
A Study for Participants With Small-Cell Lung Cancer
Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell…
- Trial name
- NCT01025284
- Testing
- LY2523355, Granulocyte colony-stimulating factor (G-CSF)
- Where
- 11 sites in United States, Romania and 1 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Ischemic Stroke
Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery
1. Circulating bone marrow and blood vessel precursors home in to sites of ischemia and aid regeneration of injured tissue 2. Increasing the number of circulating precursors will improve in regeneration of damaged brain following…
- Trial name
- GIST (NCT00809549)
- Testing
- Filgrastim
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Lymphoma
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant helps stop the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00521014
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fanconi Anemia
Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A
This is an open, Phase I / II clinical trial to evaluate the safety and efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi…
- Trial name
- FANCOLEN-1 (NCT03157804)
- Testing
- IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs), Genetically Engineered Hematopoietic Stem/Progenitor Cells, Laboratory Biomarker Analysis
- Where
- 2 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain